Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG) Short Interest Update

Key Points

• Short interest jumped 54.6% to 1,470 shares as of March 31, but still represents about 0.0% of shares sold short with a days-to-cover of only 0.3, indicating minimal short exposure despite the increase.
• Wall Street maintains a bullish stance with a consensus "Buy" rating and an average price target of $48, versus a recent open near $25.45, implying substantial analyst-implied upside.
• The company reported a quarterly loss of on $24.72 million in revenue, while several institutions (including XY Capital, UBS, Citadel, HSBC and ABC Arbitrage) have recently built or increased positions in AAPG.

Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 1,470 shares, an increase of 54.6% from the March 15th total of 951 shares. Based on an average daily trading volume, of 4,265 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the shares of the stock are sold short.

Ascentage Pharma Group International Stock Performance

NASDAQ:AAPG opened at $25.45 on Tuesday. The business's 50-day moving average price is $24.11 and its two-hundred day moving average price is $28.74. Ascentage Pharma Group International has a twelve month low of $18.52 and a twelve month high of $48.45. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million during the quarter.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently modified their holdings of AAPG. XY Capital Ltd raised its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company's stock valued at $707,000 after acquiring an additional 12,530 shares in the last quarter. UBS Group AG increased its position in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $383,000. Finally, ABC Arbitrage SA bought a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at about $204,000.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AAPG. Rodman & Renshaw began coverage on shares of Ascentage Pharma Group International in a report on Tuesday, January 13th. They issued a "buy" rating and a $48.00 price target on the stock. BTIG Research reissued a "buy" rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a "strong-buy" rating in a report on Monday, December 15th. Finally, China Intl Cap raised Ascentage Pharma Group International to a "strong-buy" rating in a report on Monday, April 6th. Two analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $48.00.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.